Market Research Logo

Acromegaly - Pipeline Review, H1 2018

Acromegaly - Pipeline Review, H1 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Acromegaly - Pipeline Review, H1 2018, provides an overview of the Acromegaly (Hormonal Disorders) pipeline landscape.

Acromegaly is a hormonal disorder that develops when pituitary gland produces too much growth hormone during adulthood. Symptoms include body odor, easy fatigue, headache, large feet, excessive height, swelling of the bony areas around a joint, widely spaced teeth and sleep apnea. Treatment includes surgery, dopamine agonists and growth hormone antagonists.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Acromegaly - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Acromegaly (Hormonal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Acromegaly (Hormonal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Acromegaly and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 6, 5, 1, 5 and 3 respectively.

Acromegaly (Hormonal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Acromegaly (Hormonal Disorders).
  • The pipeline guide reviews pipeline therapeutics for Acromegaly (Hormonal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Acromegaly (Hormonal Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Acromegaly (Hormonal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Acromegaly (Hormonal Disorders)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Acromegaly (Hormonal Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Acromegaly (Hormonal Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Introduction
Global Markets Direct Report Coverage
Acromegaly - Overview
Acromegaly - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Acromegaly - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Acromegaly - Companies Involved in Therapeutics Development
Aegis Therapeutics LLC
Amryt Pharma plc
Antisense Therapeutics Ltd
Aquestive Therapeutics
Chiasma Inc
Crinetics Pharmaceuticals Inc
Daewoong Pharmaceutical Co Ltd
Dauntless Pharmaceuticals Inc
DexTech Medical AB
Ionis Pharmaceuticals Inc
Italfarmaco SpA
leon-nanodrugs GmbH
Midatech Pharma Plc
Novartis AG
Peptron Inc
Silence Therapeutics Plc
Strongbridge Biopharma plc
Sun Pharmaceutical Industries Ltd
Acromegaly - Drug Profiles
Antisense Oligonucleotide to Inhibit Growth Hormone Receptor for Acromegaly - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AP-102 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
atesidorsen sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CRN-00808 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FP-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IONIS-GHRLRx - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ITF-2984 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lanreotide SR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Leon-03 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
octreotide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
octreotide acetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
octreotide acetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
octreotide acetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
octreotide acetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
octreotide acetate long acting - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
octreotide acetate SR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
octreotide SR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
octreotide SR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Somadex - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides to Agonize Somatostatin Receptors for Acromegaly - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
veldoreotide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Acromegaly - Dormant Projects
Acromegaly - Discontinued Products
Acromegaly - Product Development Milestones
Featured News & Press Releases
Feb 28, 2018: ATL1103/atesidorsen Early Access Program - Update
Jan 30, 2018: FDA Grants Orphan Drug Designation to Dauntless Pharmaceuticals DP1038 for the Treatment of Acromegaly
Jan 09, 2018: Midatech receives confirmation that its Q-Octreotide (MTD201) first in-human EU study is approved
Jan 08, 2018: Chiasma Reports on Significant Progress Made During 2017
Dec 22, 2017: Antisense Therapeutics Executes Agreement to Implement ATL1103 / atesidorsen Early Access Program for Patients with Acromegaly
Oct 26, 2017: Crinetics Pharmaceuticals Initiates Phase 1 Study of Lead Candidate CRN00808 for Acromegaly
Oct 19, 2017: Clinical Data from Phase 1 PK/PD Study of Octreotide for Intranasal Delivery to be Presented at North American Neuroendocrine Tumor Society Symposium
Sep 27, 2017: Chiasma Announces First Patient Is Randomized in Phase 3 CHIASMA OPTIMAL Clinical Trial of Octreotide Capsules in Patients with Acromegaly
Sep 04, 2017: Midatech Submits MTD201 CTA Filing For First-in Human Study in Carcinoid Cancer and Acromegaly
Aug 10, 2017: Chiasma Reaches Agreement with FDA under Special Protocol Assessment for a New Phase 3 Clinical Trial of Octreotide Capsules in Acromegaly
Jul 13, 2017: Crinetics Pharmaceuticals Awarded $2.8 Million SBIR Grant to Support Development of Acromegaly Drug Candidate CRN00808
May 04, 2017: Dauntless Pharmaceuticals Announces Positive Data from Phase 1 Study Investigating Octreotide Formulation for Intranasal Delivery
Mar 10, 2017: Midatech Announces Successful Initial Scale-Up of Its Sustained Release Manufacturing Facility
Feb 23, 2017: ATL1103 Update - proposed International Nonproprietary Name for ATL1103
Feb 16, 2017: Dauntless Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Octreotide Formulation for Intranasal Delivery
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Acromegaly, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Acromegaly - Pipeline by Aegis Therapeutics LLC, H1 2018
Acromegaly - Pipeline by Amryt Pharma plc, H1 2018
Acromegaly - Pipeline by Antisense Therapeutics Ltd, H1 2018
Acromegaly - Pipeline by Aquestive Therapeutics, H1 2018
Acromegaly - Pipeline by Chiasma Inc, H1 2018
Acromegaly - Pipeline by Crinetics Pharmaceuticals Inc, H1 2018
Acromegaly - Pipeline by Daewoong Pharmaceutical Co Ltd, H1 2018
Acromegaly - Pipeline by Dauntless Pharmaceuticals Inc, H1 2018
Acromegaly - Pipeline by DexTech Medical AB, H1 2018
Acromegaly - Pipeline by Ionis Pharmaceuticals Inc, H1 2018
Acromegaly - Pipeline by Italfarmaco SpA, H1 2018
Acromegaly - Pipeline by leon-nanodrugs GmbH, H1 2018
Acromegaly - Pipeline by Midatech Pharma Plc, H1 2018
Acromegaly - Pipeline by Novartis AG, H1 2018
Acromegaly - Pipeline by Peptron Inc, H1 2018
Acromegaly - Pipeline by Silence Therapeutics Plc, H1 2018
Acromegaly - Pipeline by Strongbridge Biopharma plc, H1 2018
Acromegaly - Pipeline by Sun Pharmaceutical Industries Ltd, H1 2018
Acromegaly - Dormant Projects, H1 2018
Acromegaly - Discontinued Products, H1 2018
List of Figures
Number of Products under Development for Acromegaly, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products by Targets, H1 2018
Number of Products by Stage and Targets, H1 2018
Number of Products by Mechanism of Actions, H1 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Top 10 Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report